Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced a new initiative allowing mainland China consumers to register online for vaccinations using BioNTech’s (NASDAQ: BNTX) (DE: 22Uay) mRNA COVID-19 vaccine in Hong Kong. Interested individuals are required to arrange their own travel to Hong Kong once their reservation is successfully made. This service is being facilitated by Fosun Pharma’s subsidiary, Fosun Health.
In a strategic partnership established in 2020, Fosun collaborated with BioNTech for the co-development of COVID-19 vaccines targeting the Greater China region. The vaccines, Comirnaty (BNT162b2) and the Comirnaty bivalent vaccine, which addresses the Omicron BA.4 and BA.5 subvariants, received full approvals earlier this month, having previously been granted Emergency Use Authorizations (EUAs) for individuals aged 12 and over in 2021.
Fosun has also successfully secured approvals for BioNTech’s mRNA vaccines in Macau and Taiwan. However, the regulatory review process for these vaccines in mainland China has remained stalled, leaving many consumers eager for updates on potential availability in their home market.-Fineline Info & Tech
